Our lead product candidate is a dendritic cell-based vaccine in a Phase I clinical trial to treat glioblastoma multiforme, the most common type of brain tumor. We have an exclusive worldwide license from Cedars-Sinai Medical Center for this technology which may have applicability in brain tumors, neurodegenerative disorders and multiple types of cancer. We also have a monoclonal antibody-related technology that we acquired in early 2008 that includes both monoclonal antibody candidates and a platform that allows the discovery of targets (antigens) and monoclonal antibodies for the diagnosis and treatment of cancer.